Immunization onto shaved skin with a bacterial enterotoxin adjuvant protects mice against Respiratory Syncytial Virus (RSV)

Vaccine

Volumn 21, Issue 15, 2003, Pages 1665-1671

  Godefroy, Sylvie ^a,b   Goestch, Liliane ^b   Plotnicky Gilquin, Hélène ^b   Nguyen, Thien Ngoc ^b   Schmitt, Daniel ^a   Staquet, Marie Jeanne ^a   Corvaïa, Nathalie ^b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

RSV; Skin; Vaccination

Indexed keywords

BACTERIAL TOXIN; ENTEROTOXIN; EPITOPE; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOGLOBULIN G1; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; LUNG PARENCHYMA; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; NOSE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; T LYMPHOCYTE; TH2 CELL; VIRUS INFECTION; VIRUS TITRATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIBODIES, BACTERIAL; CHOLERA TOXIN; FEMALE; MICE; MICE, INBRED BALB C; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; SKIN;

EID: 0037413956     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00733-8     Document Type: Article

References (42)

1. Simoes E.A. Respiratory Syncytial Virus infection. Lancet. 354:1999;847-852.
2. Falsey A.R. Respiratory Syncitial Virus infection in older persons. Vaccine. 16(18):1998;1775-1778.
3. Han L.L., Alexander J.P., Anderson L.J. Respiratory Syncytial Virus pneumonia among the elderly: an assessment of disease burden. J. Infect. Dis. 179(1):1999;25-30.
4. Kim H.W., Canchola J.G., Brandt C.D.et al. Respiratory Syncytial Virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89(4):1969;422-434.
5. Dudas R.A., Karron R.A. Respiratory Syncytial Virus vaccine. Clin. Microbiol. Rev. 11(3):1998;430-439.
6. Murphy B.R., Hall S.L., Kulkarni A.B.et al. An update on approaches to the development of Respiratory Syncytial Virus (RSV) and Parainfluenza Virus type 3 (PIV3) vaccines. Virus Res. 32(1):1994;13-36.
7. Power U.F., Plotnicky-Gilquin H., Huss T.et al. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a Respiratory Syncytial Virus G protein fragment. Virology. 230:1997;155-166.
8. Simard C., Nadon F., Seguin C. Trudel. Evidence that the amino acid region 124-203 of glycoprotein G from the Respiratory Syncytial Virus (RSV) constitutes a major part of the polypeptide domain that is involved in the protection against RSV infection. Antivir. Res. 28:1995;303-315.
9. Collins PL, McIntosh K, Chanock RM. Respiratory syncytial virus. In: Fields BN, editor. Virology. Raven Press: New York (NY); 1996. p. 1313-51.
10. Libon C., Corvaïa N., Haeuw J.F.et al. The serum albumin-binding region of streptococcal protein G (BB) potentiates the immunogenicity of the G130-230 RSV-A protein. Vaccine. 17:1999;406-414.
11. Power U.F., Nguyen T.N., Rietveld E.et al. Safety and immunogenicity of a novel recombinant subunit Respiratory Syncytial Virus vaccine (BBG2Na) in healthy young adults. J. Infect. Dis. 184:2001;1456-1460.
12. Le Cam NB, Nguyen TN, Corvaia N. et al. Safety and immunogenicity of BBG2Na a RSV subunit vaccine based on G derived recombinant protein in elderly: a phase II study. In: Proceedings of the 40th Interscience Conference on Antimicrobial agents and Chemotherapy (ICAAC) Abstracts. American society for Microbiology: Washington, DC; 2000. p. 493.
13. Plotnicky-Gilquin H., Goetsch L., Huss T.et al. Identification of multiple epitopes (protectopes) in the central conserved domain of a prototype human Respiratory Syncytial Virus G protein. J. Virol. 73:1999;5637-5645.
14. Goetsch L., Gonzalez A., Plotnicky-Gilquin H.et al. Targeting of nasal mucosa-associated antigen presenting cells in vivo with an outer membrane protein A from Klebsiella pneumoniae. Infect. Immun. 69(10):2001;6434-6444.
15. Glenn G., Scharton-Kersten T., Alving C. Advances in vaccine delivery: transcutaneous immunisation. Exp. Opin. Invest. Drugs. 8:1999;797-805.
16. Gockel C., Bao S., Beagley K. Transcutaneous immunization induces systemic and mucosal immunity: a potent method for targeting immunity to the female reproductive tract. Mol. Immunol. 37(9):2000;537-544.
17. Babiuk S., Baca-Estrada M., Babiuck L.A., Ewen C., Foldari M. Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. J. Control Release. 66(2-3):2000;199-214.
18. Glenn G., Taylor D., Li X., Frankel S., Montemarano A., Alving C. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med. 6(12):2000;1403-1406.
19. Glenn G.M., Rao M., Matyas G.R., Alving C.R. Skin immunization made possible by cholera toxin. Nature. 391:1998;851.
20. Glenn G., Scharton-Kersten T., Vassel R., Matyas G., Alving C. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect. Immun. 67:1999;1100-1106.
21. Glenn G., Scharton-Kersten T., Vassell R., Mallet C., Hale T., Alving C. Cutting edge: transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J. Immunol. 161:1998;3211-3214.
22. Scharton-Kersten T., Yu J., Vassell R., O'Hagan D., Alving C.R., Glenn G.M. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect. Immun. 68(9):2000;5306-5313.
23. Hammond S.A., Tsonis C., Sellins K.et al. Transcutaneous immunization of domestic animals: opportunities and challenges. Adv. Drug Delivery Rev. 43:2000;45-55.
24. Fletcher M.A., Saliou P. Vaccines and infectious disease. EXS. 89:2000;69-88.
25. Liu M.A. Vaccine developments. Nat. Med. 4(Suppl 5):1998;515-519.
26. Kaiserlian D., Etchart N. Epicutaneous and transcutaneous immunization using DNA or proteins. Eur. J. Dermatol. 9(3):1999;169-176.
27. Singh M., O'Hagan D. Advances in vaccine adjuvants. Nat. Biotechnol. 17(11):1999;1075-1081.
28. El-Ghorr A.A., Williams R.M., Heap C., Norval M. Transcutaneous immunisation with herpes simplex virus stimulates immunity in mice. FEMS Immunol. Med. Microbiol. 29:2000;255-261.
29. Taylor G., Stott E.J., Hughes M., Collins A.P. Respiratory virus infection in mice. Infect. Immun. 43:1984;649-655.
30. Yu J., Cassels F., Sharton-Kersten T.et al. Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli. Infect. Immun. 70(3):2002;1056-1068.
31. Freytag L.C., Clements J.D. Bacterial toxins as mucosal adjuvant. Curr. Top Microbiol. Immunol. 236:1999;215-236.
32. Beignon A.S., Briand J.P., Muller S., Partidos C.D. Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge. Immunology. 102:2001;344-351.
33. Bastien N., Trudel M., Simard C. Complete protection of mice from Respiratory Syncytial Virus infection following mucosal delivery of synthetic peptide vaccines. Vaccine. 17:1999;832-836.
34. Tebbey P.W., Hagen M., Hancock G.E. Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of Respiratory Syncytial Virus. J. Exp. Med. 188(10):1998;1967-1972.
35. Plotnicky-Gilquin H., Huss T., Aubry J.P.et al. Absence of lung immunopathology following Respiratory Syncytial Virus (RSV) challenge in mice immunized with a recombinant RSV G protein fragment. Virology. 258:1999;128-140.
36. Simmons C.P., Hussell T., Sparer T., Walzl G., Openshaw P., Dougan G. Mucosal delivery of a Respiratory Syncytial Virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8+ T cell responses. J. Immunol. 166(2):2001;1106-1113.
37. Dickinson B.L., Clements J.D. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun. 63(5):1995;1617-1623.
38. Giuliani M.M., Del Giudice G., Giannelli V., Dougan G., Douce G., Rappuoli R., Pizza M. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J. Exp. Med. 187(7):1998;1123-1132.
39. Douce G., Giannelli V., Pizza M., Lewis D., Everest P., Rappuoli R., Dougan G. Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants. Infect Immun. 67(9):1999;4400-4406.
40. Bergquist C., Johansson E.L., Lagergard T., Holmgren J., Rudin A. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local responses in the upper respiratory tract and the vaginal. Infect Immun. 65(7):1997;2676-2684.
41. Scharton-Kersten T., Glenn G.M., Vassell R., Yu J., Walwender D., Alving C.R. Principles of transcutaneous immunization using cholera toxin as an adjuvant. Vaccine. 17(Suppl 2):1999;S37-S43.
42. Aylward B., Lloyd J., Zaffran M., McNair-Scott R., Evans P. Reducing the risk of unsafe injections in immunization programmes: financial operational implications of various injection technologies. Bull. W.H.O. 73:1995;531-540.